A Bispecific Anti-Fluorescein × Anti-CD3 T-cell Engager in Combination with Fluoresceinated Adaptors Enables Lysis of AML Cells
{{output}}
Tumor-targeting antibodies, antibody-drug conjugates, and radionuclide antibody conjugates are established therapeutic tools in clinical use. Furthermore, bispecific T cell-engaging antibodies (TCEs) and chimeric antigen receptor (CAR) T cells are becoming the... ...
